Aptose Biosciences Inc.
Home
About
Overview
Management Team
Board of Directors
Scientific Advisory Board
Product Pipeline
Overview
CG-806 for B-cell Tumors
CG-806 for Myeloid Tumors
APTO-253
Posters & Presentations
Clinical Trials
Overview
CG-806 for CLL & NHL
CG-806 for AML
APTO-253 for AML & MDS
News
Press Releases
Presentations
Events
Investors
Overview
News & Events
Company Info
Financial Info
Stock Data
SEC Filings
SEDAR
Governance
Careers
Contact
Contact Us
Clinical Trials
Clinical Trials
Overview
CG-806 for CLL & NHL
CG-806 for AML
APTO-253 for AML & MDS
First Name
Last Name
Email
Clinical Trial
Select a trial
A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
A Study of CG-806 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS
Comments:
Submit